1, Tribody cocktail significantly reduces Ebola mortality
Lanzhou University Evidence-Based Medicine Center, led by Dr. Gao Ya, Professor Tian Jinhui, and young researcher Ge Long, cooperated with 30 researchers from 12 countries to use the network meta-analysis method to analyze Evidence-based research on the efficacy and safety of Ebola virus disease treatments. The findings, “A systematic review and network meta-analysis of the efficacy of specific drug treatments for Ebola virus disease,” were recently published online in The Lancet Microbiology.
Studies show that the triple antibody cocktail therapy Inmazeb (REGN-EB3) and the monoclonal antibody Ebanga (mAb114) can significantly reduce the mortality of patients. Because of very low-quality evidence, it is uncertain whether ZMapp and remdesivir reduce mortality. The results of this study were used by the World Health Organization Ebola virus disease treatment guidelines as the best evidence to strongly recommend Inmazeb and Ebanga for the treatment of Ebola virus disease, and were highly recognized by the academic community. (Chinese Journal of Science)
2.Junhemeng completed nearly 200 million A1 round of financing
Recently, Junhemeng Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as: Junhemeng) completed the first round of A1 round of financing. This round of financing was jointly led by Tonghua SDIC and Lightpoint Capital. , Zhonghe Oppo, Focus Fund, Hongshi Capital, etc. followed the investment, and Kaicheng Capital served as the exclusive financial advisor for this round of financing. The funds raised from this round of financing will be mainly used for the rapid advancement of the company’s product pipeline and the construction of GMP commercial production bases.
Jun Hemeng was established in November 2020. It is an international innovative company focusing on cutting-edge protein drugs in the broad market. Relying on the core team’s more than 20 years of experience in protein drug research and development and industrialization, Junhemeng has built a drug development platform with both patentability and innovation, covering the high-efficiency expression system of recombinant protein and the unique micro-denaturation separation and purification technology. , protein in vitro folding and self-assembly system, and long-term sustained release and other high-barrier, industrialized technical reserves. In addition, the company’s executive team has been working together for more than 10 years, from product initiation, R&D, production, clinical to listing, the team has jointly developed a variety of protein drugs, the team’s high stability, high collaboration, and strong cohesion escort the company’s long-term development. . (Medicine Cube Plus)
3.Genting Sunyao Announces the Approval of a Novel Antimicrobial Drug Ellacycline in Hong Kong, China for the Treatment of Complicated Intra-abdominal Infections in Adults
Recently, Genting Sunyao announced that a new antibacterial drug, Xerava, has been approved for marketing in Hong Kong, China, for the treatment of adults with complicated intra-abdominal infections. Elacycline is being developed by Tetraphase, a wholly-owned subsidiary of La Jolla, and Genting Xinyao has exclusive rights to develop and commercialize the drug in Greater China, South Korea and some key Southeast Asian markets. This time, the approved indication of the drug in Hong Kong, China is also adult complicated intra-abdominal infection. In mainland China and Taiwan, the marketing applications of Elacycline for this indication are also under review. (PR Newswire)
4.Fauci: A more dangerous new variant of the new coronavirus may appear in the United States this winter
According to the US Consumer News and Business Channel (CNBC) reported on October 7, US infectious disease expert Anthony Fauci warned that the United States is likely to see a new, A more dangerous new variant of the new coronavirus.
Fauci said at the USC event: “It is very likely that another new variant will emerge in the United States that escapes human immunity.” Fauci urged Americans not to let their guard down , because there is always a risk of an increase in cases in winter, “I think it’s a bit rash to say suddenly ‘we are completely out of (pandemic)’.” (Overseas Network)